• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HIV感染患者血脂异常的管理。

Management of dyslipidemia in HIV-infected patients.

作者信息

Malvestutto Carlos D, Aberg Judith A

机构信息

Division of Infectious Diseases & Immunology, Bellevue Hospital Center, New York University School of Medicine, NY, USA.

出版信息

Clin Lipidol. 2011 Aug;6(4):447-462. doi: 10.2217/clp.11.25.

DOI:10.2217/clp.11.25
PMID:22216062
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3249059/
Abstract

Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. As this population lives longer, coronary heart disease has become an important comorbid condition. Dyslipidemia in HIV-infected individuals is a complex condition, with multiple contributing factors including the HIV virus itself, individual genetic characteristics and antiretroviral therapy-induced metabolic changes. Effective management of dyslipidemia in this population is essential to reduce cardiovascular risk but presents multiple challenges due to interactions between antiretroviral therapy agents and lipid-lowering medications.

摘要

抗逆转录病毒疗法显著提高了艾滋病毒感染者的生存率。随着这一人群寿命的延长，冠心病已成为一种重要的合并症。艾滋病毒感染者的血脂异常是一种复杂的病症，有多种促成因素，包括艾滋病毒本身、个体遗传特征以及抗逆转录病毒疗法引起的代谢变化。有效管理这一人群的血脂异常对于降低心血管风险至关重要，但由于抗逆转录病毒治疗药物与降脂药物之间的相互作用，这带来了多重挑战。

相似文献

1
Management of dyslipidemia in HIV-infected patients.HIV感染患者血脂异常的管理。
Clin Lipidol. 2011 Aug;6(4):447-462. doi: 10.2217/clp.11.25.
2
Evaluation and management of dyslipidemia in patients with HIV infection.HIV感染患者血脂异常的评估与管理。
J Gen Intern Med. 2002 Oct;17(10):797-810. doi: 10.1046/j.1525-1497.2002.20201.x.
3
Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons.HIV感染者的冠心病风险、血脂异常及管理
HIV Clin Trials. 2004 Nov-Dec;5(6):416-33. doi: 10.1310/P07M-HNT8-L08G-5TKU.
4
Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.西班牙VACH队列中接受高效抗逆转录病毒治疗（HAART）的HIV-1感染受试者的血脂异常与心血管疾病风险因素管理
Open AIDS J. 2008;2:26-38. doi: 10.2174/1874613600802010026. Epub 2008 Mar 24.
5
Management of metabolic complications and cardiovascular risk in HIV-infected patients.HIV 感染者代谢并发症及心血管风险的管理。
AIDS Rev. 2010 Oct-Dec;12(4):231-41.
6
[HIV infection, antiretroviral therapy, and endothelium].[人类免疫缺陷病毒感染、抗逆转录病毒疗法与内皮细胞]
Herz. 2005 Sep;30(6):472-80. doi: 10.1007/s00059-005-2740-3.
7
Dyslipidemia and lipid management in HIV-infected patients.HIV 感染者的血脂异常与血脂管理。
Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):144-7. doi: 10.1097/MED.0b013e328344556e.
8
Managing dyslipidemia in HIV/AIDS patients: challenges and solutions.管理艾滋病毒/艾滋病患者的血脂异常：挑战与解决方案。
HIV AIDS (Auckl). 2014 Dec 17;7:1-10. doi: 10.2147/HIV.S46028. eCollection 2015.
9
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.成人感染人类免疫缺陷病毒并接受抗逆转录病毒治疗时血脂异常的评估与管理初步指南：成人艾滋病临床试验组心血管疾病重点小组的建议
Clin Infect Dis. 2000 Nov;31(5):1216-24. doi: 10.1086/317429. Epub 2000 Nov 7.
10
Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.HIV感染患者血脂异常及其他心血管危险因素的管理：基于病例的综述
Top HIV Med. 2006 Oct-Nov;14(4):134-9.

引用本文的文献

1
Optimizing statin therapy in HIV-infected patients: a review of pharmacotherapy considerations.优化HIV感染患者的他汀类药物治疗：药物治疗考量综述
BMC Cardiovasc Disord. 2025 May 31;25(1):421. doi: 10.1186/s12872-025-04887-2.
2
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy.在HIV-RNA检测不到的艾滋病毒感染者中选定的合并症与抗逆转录病毒治疗转换的概率：意大利的一项回顾性分析
J Antimicrob Chemother. 2025 Jul 1;80(7):1849-1859. doi: 10.1093/jac/dkaf137.
3
Apolipoprotein E genetic variation, atherogenic index and cardiovascular disease risk assessment in an African population: An analysis of HIV and malaria patients in Ghana.载脂蛋白 E 基因变异、致动脉粥样硬化指数与非洲人群心血管疾病风险评估：加纳 HIV 和疟疾患者分析。
PLoS One. 2023 May 3;18(5):e0284697. doi: 10.1371/journal.pone.0284697. eCollection 2023.
4
Subclinical Atherosclerosis Is Associated with Discrepancies in BAFF and APRIL Levels and Altered Breg Potential of Precursor-like Marginal Zone B-Cells in Long-Term HIV Treated Individuals.亚临床动脉粥样硬化与长期接受抗逆转录病毒治疗的HIV感染者体内BAFF和APRIL水平的差异以及前体样边缘区B细胞的调节性B细胞潜能改变有关。
Vaccines (Basel). 2022 Dec 30;11(1):81. doi: 10.3390/vaccines11010081.
5
The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study.韩国HIV感染患者肾功能不全的发病率及危险因素：韩国HIV/AIDS队列研究
Infect Chemother. 2022 Sep;54(3):534-541. doi: 10.3947/ic.2022.0101.
6
Atherosclerosis in HIV Patients: What Do We Know so Far?HIV 患者的动脉粥样硬化：目前我们了解多少？
Int J Mol Sci. 2022 Feb 24;23(5):2504. doi: 10.3390/ijms23052504.
7
Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.免疫抑制和HIV病毒血症与老年HIV感染者更易致动脉粥样硬化的血脂谱相关。
AIDS Res Hum Retroviruses. 2019 Jan;35(1):81-91. doi: 10.1089/AID.2018.0145. Epub 2018 Nov 27.
8
Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy.影响基于奈韦拉平的抗反转录病毒疗法的 HIV 感染患者高密度脂蛋白胆固醇的因素。
Indian J Med Res. 2017 May;145(5):641-650. doi: 10.4103/ijmr.IJMR_1611_15.
9
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.接受阿巴卡韦/拉米夫定加阿扎那韦治疗（无论是否联用利托那韦）144周的HIV-1感染受试者按性别划分的反应情况。
HIV AIDS (Auckl). 2017 Mar 3;9:51-61. doi: 10.2147/HIV.S108756. eCollection 2017.
10
Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study.津巴布韦HIV患者9个月内心血管疾病风险状况的变化：一项随访研究
HIV AIDS (Auckl). 2016 Oct 25;8:165-174. doi: 10.2147/HIV.S113206. eCollection 2016.

本文引用的文献

1
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.与包含阿巴卡韦的初始抗逆转录病毒治疗相关的心肌梗死风险较低：来自 ACTG A5001/ALLRT 的短期和长期结果。
Clin Infect Dis. 2011 Apr 1;52(7):929-40. doi: 10.1093/cid/ciq244.
2
Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein.载脂蛋白 B/A-I 和总胆固醇/高密度脂蛋白胆固醇比值均可独立于非脂质危险因素、白蛋白尿和 C 反应蛋白预测普通人群的心血管事件。
J Intern Med. 2011 Feb;269(2):232-42. doi: 10.1111/j.1365-2796.2010.02323.x. Epub 2010 Dec 3.
3
Dyslipidemia and its Treatment in HIV Infection.HIV感染中的血脂异常及其治疗
Top HIV Med. 2010 Aug-Sep;18(3):112-8.
4
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.欧洲线粒体 DNA 单倍群与艾滋病临床试验组研究 A5142 中抗逆转录病毒治疗期间的代谢变化。
AIDS. 2011 Jan 2;25(1):37-47. doi: 10.1097/QAD.0b013e32833f9d02.
5
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.普伐他汀和非诺贝特治疗可改善 ACTG 5087 中的致动脉粥样硬化脂质谱，但不能改善炎症标志物。
J Clin Lipidol. 2010 Jul-Aug;4(4):279-87. doi: 10.1016/j.jacl.2010.04.003.
6
Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.HIV 未感染成年人中低剂量利托那韦与雷特格韦的餐后血脂效应。
AIDS. 2010 Jul 17;24(11):1727-31. doi: 10.1097/QAD.0b013e32833ac7be.
7
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.预测HIV感染患者的心血管疾病风险：抗HIV药物不良反应研究的数据收集
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. doi: 10.1097/HJR.0b013e328336a150.
8
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.一项旨在确定在稳定的背景抗逆转录病毒治疗基础上添加替诺福韦对血脂异常影响的初步研究：ACTG 5206。
AIDS. 2010 Jul 17;24(11):1781-4. doi: 10.1097/QAD.0b013e32833ad8b4.
9
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.拉替拉韦与依非韦伦方案治疗初治 HIV-1 感染患者：96 周疗效、持久性、亚组、安全性和代谢分析。
J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287.
10
Drug-drug interactions between raltegravir and pravastatin in healthy volunteers.健康志愿者中雷迪帕韦与普伐他汀的药物相互作用。
J Acquir Immune Defic Syndr. 2010 Sep;55(1):82-6. doi: 10.1097/QAI.0b013e3181d9a354.